Paradigm Health
-16%
est. 2Y upside i
Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers.
Rank
#2666
Sector
Healthcare Technology
Est. Liquidity
~5Y
Data Quality
Data: LowThe equity upside is highly uncertain due to complete lack of financial data.
Last updated: July 21, 2026
Assuming strong adoption and FDA collaboration leading to high growth; equity value doubles to $1.5B despite 20% dilution.
Valuation stagnant at $750M; no material exit progress within 2 years; dilution reduces effective upside to near zero.
Failure to achieve commercial traction or regulatory setbacks; preference stack ($281M) wipes out common equity, resulting in total loss.
Preference Stack Risk
severeFunding Intensity
3750%Total preferred stock ($281M) equals 37% of assumed entry valuation ($750M), severely diluting common equity in downside scenarios.
Dilution Risk
highWith $281M raised and no path to breakeven disclosed, additional funding rounds are likely within 2 years, further diluting common holders by an estimated 20%.
Secondary Liquidity
noneNo secondary market activity reported; liquidity expected only upon exit (IPO or acquisition), likely 4-5 years away.
Questions to Ask at the Interview
Strategic questions based on Paradigm Health's data — designed to show you've done your homework.
- 1
“What is your current annual recurring revenue and growth rate?”
- 2
“How do you plan to achieve profitability and reduce reliance on venture funding?”
- 3
“What are the typical equity grant sizes and liquidity opportunities for employees?”
Community
Valuation Sentiment
Our model estimates -16% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.